Published on
August 31, 2026
- 12:00 GMT
NovaSpira Receives MFDS Approval to Start Phase 1 Trial of NS 342 (GPC3x4-1BB Bispecific) in Advanced Solid Tumors
CHATHAM, NJ, UNITED STATES, August 31, 2026 /EINPresswire.com/ -- NovaSpira Biotherapeutics today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved the company’s updated Phase 1 clinical trial plan for NS‑ …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
